Mechanically, TUG1 can promote cisplatin resistance in ESCC through upregulating Nrf2 or epigenetically suppressing PDCD4 expression via EZH2 (Xu et al., 2018a; Zhang et al., 2019c). Here, EZH2 is linked to esophageal squamous cell carcinoma.